Navigation Links
First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
Date:12/7/2008

es in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at www.alexionpharm.com.


    [ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2008, and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
4. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
11. First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Trovagene, Inc., (NASDAQ: ... today that Alberto Bardelli , Ph.D., has joined ... the first to identify mutations in the kinase genes ... Currently, he is at the Department of Oncology, Torino ... Italy . "Alberto,s work ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... , Sept. 17, 2014 Research ... "Global Breast Cancer Market 2014-2018" report to ... by the uncontrolled growth of cancerous cells in the ... however, male breast cancer is rare. Histologically, breast cancer ... cancer and other undifferentiated carcinoma. Ductal carcinoma is the ...
Breaking Medicine Technology:Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 2Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3
... (OTC Bulletin Board: CGNH ) announced today that ... 2 Class B common stockholders a "Stockholder Questionnaire," which the ... count of the Company,s shares currently held in "street ... If you have not received the Stockholder Questionnaires via ...
... VILLAGE, Nev., March 8, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... rate for its 2.00% Convertible Senior Notes due February 15, 2012 ... 15, 2015 (the 2015 Notes) effective March 7, 2011, in connection ... to all stockholders who own shares of PDL on March 8, ...
Cached Medicine Technology:CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires 2PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015 2
(Date:9/17/2014)... September 17, 2014 In ongoing ... Inc.’s Drug Benefit News (DBN) continues to find ... in its Aug. 8 issue , CVS Caremark ... lists for 2015 each cut more drugs than ... savings these exclusions are likely to achieve. Despite ...
(Date:9/17/2014)... Washington, DC (PRWEB) September 17, 2014 ... family history. Along with regular screening and examination, a ... In this episode of Epicure with the Chef ... GWMFA Urologist Dr. Paul Rusilko to prepare a delicious ... in our western diets that influence risk of prostate ...
(Date:9/17/2014)... 2014 “North America Gynecological Devices ... on the North America Gynecological Devices market. The ... volume (in units) and average prices (in US ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) ... , Endometrial Ablation Devices (Thermal Balloon, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Stand Up ... and music, returns to the Theater at Madison Square ... the Bob Woodruff Foundation (BWF) and New York Comedy ... returning service members, veterans and their families. , ... John Mulaney, John Oliver, Bruce Springsteen, Brian Williams and ...
(Date:9/17/2014)... Alpharetta, GA (PRWEB) September 17, 2014 ... Background Screeners (NAPBS®) Background Screening Credentialing Council ... demonstrated compliance with the Background Screening Agency ... formally recognized as BSCC-Accredited. , S2Verify, ... , Each year, U.S. employers, organizations and ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 2Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 3Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 5Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 2Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 3
... , , COLCHESTER, ... College of Pharmacy and Health Sciences opened its Vermont Satellite Campus ... in scenic Colchester, Vermont, is home to the only pharmacy program ... campus offers a four year program culminating in a Doctor of ...
... ... Eye Institute of Utah – a prominent Salt Lake City, Utah ... a national award recognizing the quality of its work. Known as one of ... Springs, Wyoming location has been named by the U.S. Commerce Association as one ...
... U.S. Commerce ... living with Diabetes. , ... Raton, FL (PRWEB) August 31, 2009 -- Leading provider of diabetes medical supplies, American Diabetes ... Medical Supplies category by the U.S. Commerce Association (USCA). The company is aiding those ...
... ... solution to address current challenges in public health reporting and to improve the early detection, ... , ... 2009 -- Orion Health, Inc. and Cisco today announced the Rhapsody® ...
... , , MAASTRICHT, ... VAR ) is introducing the world,s first low-energy radiotherapy ... clinics. Varian,s UNIQUE(TM) radiotherapy system is expected to make advanced ... around the world. , , "This package ...
... , , NUTLEY, N.J., ... that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) ... kidney and heart transplant patients (4 months to 16 years of ... also approved a new pediatric oral solution formulation for Valcyte, which ...
Cached Medicine News:Health News:Albany College of Pharmacy and Health Sciences Opens Vermont Satellite Campus 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 3Health News:Provider of Diabetes Medical Supplies Receives 2009 Best of Boca Raton Award 2Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 2Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 3Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 4Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 2Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 3Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 2Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 3Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 4
... protection, our conventional aprons are ... sturdy 2 webbed straps that ... hook fasteners. The straps can ... the apron. Our conventional apron ...
Unshielded...
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... MOST Options System is designed to ... of the knee or hip to ... provides the potential for restoration of ... the requirements of a rotating hinge ...
Medicine Products: